CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.680
+0.020 (0.55%)
At close: Jul 15, 2026, 4:00 PM EDT
3.694
+0.014 (0.38%)
After-hours: Jul 15, 2026, 7:40 PM EDT
CytomX Therapeutics Employees
CytomX Therapeutics had 69 employees as of December 31, 2025. The number of employees decreased by 52 or -42.98% compared to the previous year.
Employees
69
Change (1Y)
-52
Growth (1Y)
-42.98%
Revenue / Employee
$515,101
Profits / Employee
-$900,623
Market Cap
801.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | -52 | -42.98% | 69 | 0 |
| Dec 31, 2024 | 121 | -1 | -0.82% | 119 | 2 |
| Dec 31, 2023 | 122 | 4 | 3.39% | 120 | 2 |
| Dec 31, 2022 | 118 | -60 | -33.71% | 116 | 2 |
| Dec 31, 2021 | 178 | 32 | 21.92% | 174 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 465 |
| Omeros | 175 |
| Rigel Pharmaceuticals | 174 |
| Neurogene | 131 |
| Aura Biosciences | 113 |
| Odyssey Therapeutics | 100 |
| Aclaris Therapeutics | 73 |
| Zevra Therapeutics | 61 |
CTMX News
- 5 weeks ago - CytomX Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - CytomX Therapeutics expands licensing agreement with Regeneron - TheFly
- 6 weeks ago - CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - GlobeNewsWire
- 7 weeks ago - CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewsWire
- 2 months ago - CytomX Therapeutics initiated with an Outperform at Wolfe Research - TheFly
- 2 months ago - CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs - GlobeNewsWire
- 2 months ago - CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright - TheFly